Company ProfilePremium

Celyad Oncology SA

Company Profile Analysis

Ticker: CYAD.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Celyad Oncology SA - Company showcase

Year Founded & Workforce

2004

4 Employees

Celyad Oncology SA logo

Celyad Oncology SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Celyad Oncology SA Overview

Celyad Oncology is a Belgian former clinical-stage CAR-T cell therapy developer that has been reduced, through a series of restructurings between 2022 and 2026, to an intellectual-property holding and licensing shell. It pioneered NKG2D-receptor-based CAR-T cells (licensed from Dartmouth College via Celdara Medical) and non-gene-edited allogeneic approaches using T-cell receptor inhibitory molecules and short-hairpin RNA (shRNA), but discontinued clinical development in late 2022 and all R&D in August 2025. It sold its research facility (EUR 3M, 2025) and its legacy C-CATHez cardiac catheter to CellProthera (up to EUR 5M deferred plus royalties, February 2026). With roughly four employees, a treasury position of EUR 0.1M at 30 June 2026 topped up by a EUR 0.5M Fortress placement, and a market value near EUR 8M, Celyad's equity value now rests on monetising its CAR-T patent estate through out-licensing — under the effective control of Fortress Investment Group.


Company self-description

In its current boilerplate, Celyad describes itself as a biotechnology company focused primarily on unlocking the potential of its intellectual property, headquartered in Mont-Saint-Guibert (FY2025 release, 2 Apr 2026). The 2025 business highlights state that it remains focused on partnering its IP and has progressed discussions with potential partners for selected out-licensing of its technologies.

Independent characterisation

Celyad is no longer an operating biotech. It is a listed IP vehicle whose assets are (i) a CAR-T patent portfolio — NKG2D-based CARs, allogeneic platforms (TIM and shRNA), and related know-how — and (ii) contingent consideration from the C-CATHez sale. It has no product revenue, no clinical programmes, no laboratory, and a skeletal staff. Its cost base has been cut from ≈ EUR 30M per year (2021–2022 R&D plus G&A) to an H1 2026 operating loss of EUR 1.2M. Its survival depends on small, repeated equity injections from Fortress, which controls the company. Value realisation would come from: licence fees/milestones/royalties from third parties using its patents; milestone payments from CellProthera; or a corporate transaction (reverse merger/shell sale) leveraging the listing.

Revenue model

Revenue typeFY2025Comment
Product sales≈0Residual EUR 21k revenue in FY2025 (cost of sales EUR 8k) — likely legacy catheter or service items
Licensing / royalties0 recognisedTarget business model; no firm licence signed as of FY2025 (no change in fair value of Dartmouth/Celdara contingent liabilities)
Asset-sale considerationRecognised in other incomeResearch-facility sale gain EUR 2.3M (2025); C-Cath gain (H1 2026)
Grants / R&D tax creditsRecognised in other incomeWalloon Region grant income and R&D tax-credit derecognition gains (2025)

Value-chain position and customers

Upstream IP originator/licensor in cell therapy. Prospective counterparties are CAR-T and cell-therapy developers (pharma and biotech) that may need freedom-to-operate under Celyad's NKG2D or allogeneic patents, plus CellProthera for the catheter. End-markets: oncology cell therapy (haematological and solid tumours) and, via the catheter, cardiac regenerative medicine.

Strategy

Stated strategy

  • Partner and out-license the IP portfolio; selective out-licensing discussions reported as progressing (FY2025 release).

  • Run the company at minimal cost after discontinuing R&D and selling physical assets (Aug 2025 release: intends to sell remaining assets to focus on IP).

  • Maintain listing and continuity — the board proposed continuation under the Belgian "alarm bell" procedure (Art. 7:228 BCCA) at the 20 May 2026 AGM.

Initiatives in the last 24 months

DateInitiativeDetailStatus
24 Jun 2025Strategic reviewAsset sales, restructuring, M&A, financing all consideredExecuted via asset sales and restructuring
29 Jul 2025EUR 1M Fortress placementBridge fundingClosed
25 Aug 2025R&D discontinuationSignificant workforce reductionCompleted
30 Sep 2025Research facility saleEUR 3M; gain EUR 2.3MCompleted
2,025Termination of Walloon-subsidised research contractsResearch results transferred to Region; RCAs reducedCompleted
12 Feb 2026C-CATHez sale to CellProtheraUp to EUR 5M milestones + royaltiesCompleted; gain booked H1 2026
14–16 Jul 2026EUR 0.5M Fortress placementRunway extended from Q3 2026 to ≈ mid-Q2 2027Closed

Guidance

No financial targets. Cash runway guidance: "until 2027" (H1 2026 release); press reporting of the July placement cites ≈ mid-Q2 2027.

Products & Services

Celyad has no marketed products. Its "portfolio" consists of IP assets and discontinued programmes.

Pricing model: licensing terms not disclosed.

Product Portfolio

AssetTypeDescriptionStatusNotes

NKG2D CAR-T IP

Patent family

CAR constructs using the NKG2D receptor to target NKG2D ligands on tumour cells; in-licensed from Dartmouth via Celdara (OnCyte acquisition)

Available for out-licensing

Contingent consideration owed to Dartmouth/Celdara on sublicensing

Allogeneic TIM platform

Patent family / know-how

Non-gene-edited allogeneic CAR-T using a T-cell receptor inhibitory molecule (basis of CYAD-101)

Development discontinued

—

shRNA allogeneic platform

Licensed platform / patents

All-in-one vector shRNA to knock down TCR/other targets (Horizon Discovery SMARTvir), basis of CYAD-200 series incl. CYAD-211 (BCMA)

Discontinued; intangible fully impaired in 2022

Impairment EUR 35.1M (2022)

CYAD-01 / CYAD-02

Autologous NKG2D CAR-T candidates

Clinical programmes in AML/MDS

Discontinued

—

CYAD-101

Allogeneic NKG2D CAR-T

Colorectal cancer programme

Halted (2022)

—

CYAD-211

Allogeneic anti-BCMA shRNA CAR-T

Multiple myeloma

Discontinued late 2022

Dealroom

C-CATHez

Transendocardial injection catheter

Delivers cells directly into damaged myocardium

Sold to CellProthera, Feb 2026 (up to EUR 5M + royalties)

Gain recognised H1 2026

Walloon Region-funded research results

Research IP

Results of subsidised contracts

Rights transferred to the Walloon Region in 2025

Generated grant income

Financial Narrative

Income statement

Sources: FY2022 release (FY2021–FY2022 columns), FY2023 release, FY2025 release (FY2024–FY2025 IFRS statements). FY2023 R&D/G&A/other income lines were not captured from primary sources. Revenue "–" in the FY2022 release is shown as 0. Margins are not meaningful given negligible revenue. EBITDA is not reported; an aggregator (Parqet) shows FY2025 EBITDA of −EUR 3.58M.

Commentary. The trajectory is one of deliberate shrinkage. In 2021–2022 Celyad ran a ≈ EUR 30M annual R&D+G&A cost base. FY2022's loss was inflated by a EUR 35.1M impairment (partly offset by a EUR 14.7M reversal of contingent consideration) when clinical programmes were stopped. FY2023 losses fell to EUR 8.5M under "Celyad 2.0." By FY2024 combined R&D and G&A were ≈ EUR 6.4M. FY2025's reported net profit of EUR 0.83M is entirely non-recurring: other income of EUR 8.26M came from (i) grant income recognised when Celyad ended Walloon-subsidised research contracts and transferred results to the Region, (ii) R&D tax-credit liability derecognition, and (iii) a EUR 2.3M gain on the research facility sale. Underlying costs actually rose in 2025 (R&D +EUR 0.2M; G&A +EUR 0.6M) because of severance. H1 2026 operating loss was EUR 1.2M (vs EUR 3.7M in H1 2025), reflecting the new minimal cost base and a C-Cath sale gain.

Balance sheet

Source: FY2025 consolidated statement of financial position (FY2024–FY2025); treasury FY2021–FY2022 from FY2022 release. FY2025 includes assets held for sale EUR 0.682M (C-Cath) and liabilities held for sale EUR 0.100M. A "capital reduction reserve" of EUR 320.7M offsets historical losses. Recoverable cash advances (RCAs) are Walloon Region funding repayable on commercial success — debt-like; the large reduction in 2025 reflects the transfer of research rights to the Region.

Net debt (FY2025, derived): RCAs EUR 0.621M − cash EUR 1.708M = net cash EUR 1.09M.

Interim: Cash at 30 Jun 2025 EUR 0.8M; at 30 Jun 2026 EUR 0.1M (H1 2026 release).

Cash flow: notes and sources

Sources: FY2022, FY2023, FY2025 releases. Note an inconsistency inside the FY2025 release: the headline table labels the EUR 2.5M/2.8M net cash burn as "net cash used in operations," while the text and cash table give EUR 6.9M/5.7M as net cash used in operations. The cash table values are used here. Financing in 2025 includes the EUR 1M Fortress placement; investing includes the EUR 3M facility sale. H1 2026 operating cash use: EUR 1.5M (vs EUR 3.3M in H1 2025).

Ratios

FY2025 ROE/ROA on closing balances (derived) and driven by one-off gains — not meaningful as indicators of earning power. ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are not meaningful for a pre-revenue IP shell.

Interim trend

Sources: H1 2025 release; H1 2026 coverage (Fortuneo, ABC Bourse, Idéal Investisseur). One source gives H1 2025 net loss as EUR 3.3M and EPS −EUR 0.09; the company's H1 2025 release gives EUR 3.7M — minor discrepancy noted; EUR 3.7M used.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Revenue by Segment (%)

Segment metricFY2023FY2024FY2025

Single segment revenue (EUR Mn)

—0.1860.021

Single segment operating profit (EUR Mn)

-8.5-5.8580.881

Share of total revenue (%)

100100100

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR Mn)

00—0.1860.021

Gross profit (EUR Mn)

———0.1730.013

R&D expenses (EUR Mn)

20.818.9—3.2353.416

G&A expenses (EUR Mn)

9.910.5—3.1983.779

Change in fair value of contingent consideration (EUR Mn)

0.814.7—00

Impairment of oncology intangibles (EUR Mn)

0-35.1000

Other income/(expenses) net (EUR Mn)

3.49.0—0.4018.063

Operating profit/(loss) (EUR Mn)

-26.4-40.9-8.5-5.8580.881

Pre-tax profit/(loss) (EUR Mn)

———-5.8240.830

Net profit/(loss) (EUR Mn)

-26.5-40.9-8.5-5.8240.830

EPS basic = diluted (EUR)

-1.70-1.81-0.33-0.140.018

Dividend per share (EUR)

00000

Balance Sheet

MetricFY2021FY2022FY2024FY2025

Total assets (EUR Mn)

——9.9284.298

Cash & equivalents (EUR Mn)

—12.44.2001.708

Treasury position incl. short-term investments (EUR Mn)

30.012.44.21.7

Lease liabilities total (EUR Mn)

——0.9050

Recoverable cash advances total (EUR Mn)

——4.8340.621

Equity (EUR Mn)

——0.5112.436

Goodwill & intangibles (EUR Mn)

——0.4050.016

Working capital – current assets less current liabilities (EUR Mn)

——3.6691.679

Accumulated deficit (EUR Mn)

——-364.196-363.366

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Net cash used in operations (EUR Mn)

-26.6-28.0-15.2-5.680-6.900

Net cash from/(used in) investing (EUR Mn)

———-0.1033.007

Net cash from financing (EUR Mn)

———2.9831.394

Net cash burn – change in treasury (EUR Mn)

———-2.800-2.499

Dividends paid (EUR Mn)

00000

Buybacks (EUR Mn)

00000

Financial Ratios (x) and Returns & Leverage Ratios (%)

RatioFY2024FY2025

Current ratio (x, derived)

2.291.92

Equity / total assets (%)

5.156.7

ROE (%)

—34.1

ROA (%)

—8.4

Cash Flow and Per-Share Data

MetricH1 2024H1 2025H1 2026

Net profit/(loss) (EUR Mn)

-3.0-3.7-1.2

Net cash used in operations (EUR Mn)

-2.8-3.3-1.5

Cash & equivalents at period end (EUR Mn)

6.20.80.1

EPS (EUR)

—-0.09-0.027

Share Price & Returns

Reference pointPriceSource

16 Oct 2026 (Frankfurt)

EUR 0.174

finanznachrichten.de

~Jul 2026 (placement reference)

≈ EUR 0.235 (10-day VWAP implied by EUR 0.20 at 15% discount, derived)

Company release

12 Jun 2026

USD 0.30

PitchBook

Dec 2021 (Fortress placement)

USD 5.00 per share

Company release

Performance

Value

—

5-year

≈ −96% from the USD 5.00 placement price (Dec 2021) to ≈ EUR 0.17 (derived, approximate FX)

—

Valuation Snapshot

MultipleValue

Market cap (derived)

≈ EUR 8M

P/E

Not meaningful (one-off profit)

EV/EBITDA

Not meaningful (negative EBITDA)

P/B (FY2025 equity EUR 2.44M)

≈ 3.4x (derived)

Analyst Conclusions

Guidance

No operating guidance. Cash runway "until 2027" after the July 2026 EUR 0.5M placement (H1 2026 release); press coverage of the placement cites extension to ≈ mid-Q2 2027. No consensus estimates exist.

Bull case

  1. Licensing optionality at a tiny valuation: a single licence fee in the low single-digit EUR millions would be material against an ≈ EUR 8M market value and ≈ EUR 2–3M annual cost base.

  2. CellProthera milestones: up to EUR 5M deferred consideration plus royalties if the Phase 3 catheter-enabled therapy progresses.

  3. Shell value: a listed Euronext vehicle with Fortress control could be used for a reverse merger, creating value for remaining holders.

Bear case

  1. Perpetual dilution: each funding round (latest at EUR 0.20) erodes minority value; Fortress's voting control grows.

  2. No proven IP demand: no licence signed despite two years of IP-focused strategy; contingent payments to Dartmouth/Celdara reduce net economics.

  3. Going-concern and liquidation risk: cash of EUR 0.1M at mid-2026 and an auditor material-uncertainty paragraph mean survival depends entirely on Fortress.

Catalysts and monitorables (next 12 months)

  • Any out-licensing agreement or patent-assertion action.

  • CellProthera Phase 3 start (milestone triggers).

  • Further Fortress placements, or a squeeze-out/delisting proposal.

  • Outcome of any reverse-merger or strategic transaction.

  • FY2026 results (≈ April 2027) and auditor going-concern opinion.

  • Tolefi stance (transparency notification of 28 Jul 2026; supermajority rights).

Analyst verdict

Celyad Oncology is a cautionary arc in European biotech: from a Nasdaq-listed CAR-T pioneer that raised a USD 100M US IPO and a USD 32.5M premium placement from Fortress in December 2021, to a four-person IP shell holding EUR 0.1M of cash in June 2026. The decline was driven by clinical setbacks, a EUR 35.1M write-off of its allogeneic and shRNA assets in 2022, and a funding environment that left no room for a sub-scale cell-therapy developer. Management has since done what was necessary: discontinued R&D, sold the laboratory for EUR 3M, monetised the legacy C-CATHez catheter for up to EUR 5M in deferred consideration, ended subsidised research contracts (unwinding most recoverable cash advances), and cut the cash burn to roughly EUR 3M a year.

The FY2025 "profit" should be ignored as an earnings signal — it is entirely the product of one-off grant recognition, tax-credit derecognition and asset-sale gains. The relevant questions are whether the NKG2D and allogeneic patent estate has commercial read-through to products that others are developing, and whether Fortress intends to keep the vehicle alive long enough to find out. Fortress's willingness to fund EUR 0.5M at a discount in July 2026 suggests it sees residual value — but its terms also concentrate control (≈ 68.8% of votes) and dilute minorities.

For outside shareholders, Celyad is best viewed as a binary, option-like micro-cap with a material probability of further dilution and a non-trivial probability of eventual delisting or liquidation. Upside exists from a licence deal, CellProthera milestones, or a shell transaction, but none is visible or contracted. We would not regard the equity as investable on fundamentals; it is suitable only for speculative capital that accepts total-loss risk and minimal governance leverage against a controlling shareholder.


Sources consulted

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureNotes

Hannes Iserentant

General Manager; investor/media contact

At least since Apr 2026

Named on FY2025 release as General Manager

Matt Kane

Chief Executive Officer (as of Aug 2025)

—

Quoted in R&D discontinuation release (Aug 2025); current status not confirmed — FY2025 release lists only a General Manager as contact, suggesting possible departure

David Georges

Contact named on 2025 releases (role not specified; possibly finance/IR)

—

Business Wire contact block

Executive Leadership Team by Director

DirectorRoleAffiliationNotes

Fortress-nominated directors (affiliate represented by Michel Lussier, co-opted 2023)

Non-executive

Fortress Investment Group

Fortress has had the right to nominate two directors while holding ≥10% (2021 rights agreement); did not vote on July 2026 related-party placement

Tolefi-nominated director

Non-executive

Tolefi SA

Right to one seat while holding ≥5% (2023 agreement)

Independent directors (names not captured)

Non-executive

Independent

Formed the Art. 7:97 committee approving the July 2026 placement

Major Shareholders

Holder% shares% voting rightsDate / Source

CFIP CLYD (UK) Ltd / Fortress Investment Group

≈ 60.5–60.7

≈ 68.75–68.84

Post 16 Jul 2026 placement (company release; Investing.com)

Tolefi SA

Not disclosed post-dilution

—

Transparency notification published 28 Jul 2026 (content not captured); ≈16% after Sep 2023 tranche, diluted thereafter

Free float / others

≈ 25–30 (derived)

—

Derived

“—” = not publicly disclosed.

Competitive Landscape

Competitors by Segment

AreaCompanyPositioning relative to Celyad

Autologous CAR-T (approved products)

Novartis

Kymriah; potential licensee/historical licensee

Autologous CAR-T

Gilead/Kite

Yescarta, Tecartus

Autologous CAR-T

Bristol Myers Squibb

Breyanzi, Abecma

Autologous CAR-T

Johnson & Johnson / Legend Biotech

Carvykti (BCMA)

Allogeneic CAR-T

Allogene Therapeutics

Gene-edited allogeneic leader

Allogeneic CAR-T

Cellectis

TALEN-edited allogeneic; IP-heavy French peer

Allogeneic CAR-T

Caribou Biosciences

CRISPR-edited allogeneic

NKG2D-based cell therapy

Nkarta

NKG2D-CAR NK cells — closest technology overlap

Allogeneic/in vivo CAR

CRISPR Therapeutics

Gene-edited allogeneic programmes

IP-licensing shells

Various

Compete for licensee attention

Benchmark

Celyad FY2025

Peers

Revenue

EUR 0.021M

—

R&D intensity

N/M

—

Margins

N/M

—

Company Snapshot

4

Employees

2004

Founded

Mont-Saint-Guibert, Belgium

Headquarters

SWOT Analysis

Strengths

  • Drastically reduced burn — H1 2026 operating cash use EUR 1.5M vs EUR 3.3M in H1 2025 and EUR 26.6M for FY2021.
  • Clean, small balance sheet — no lease liabilities and RCAs reduced to EUR 0.621M at end-2025 (from EUR 4.83M).
  • Committed controlling shareholder — Fortress funded the company in 2021, 2023, 2025 and 2026.
  • Contingent upside from C-Cath — up to EUR 5M milestones plus royalties (Feb 2026).
  • Legacy IP in a commercial field — NKG2D CAR-T and allogeneic patents.
  • Listed vehicle — Euronext Brussels listing has optionality for a reverse merger.

Weaknesses

  • Near-zero cash — EUR 0.1M at 30 Jun 2026 before a EUR 0.5M top-up.
  • Going-concern uncertainty — BDO paragraph in FY2024 and FY2025 opinions.
  • No revenue engine — EUR 21k revenue in FY2025; no licence signed.
  • No R&D capability — discontinued Aug 2025; ≈4 employees.
  • Net assets below 25% of capital (BE-GAAP) — alarm-bell procedure triggered.
  • Profit quality — FY2025 profit entirely from one-off other income (EUR 8.26M).

Opportunities

  • Out-licensing deals — discussions reported as progressing (FY2025 release).
  • CellProthera Phase 3 — milestone triggers on progress.
  • Reverse merger / shell transaction — listing and Fortress control could facilitate.
  • Patent assertion — if third-party products use NKG2D or allogeneic methods covered by its claims.
  • Additional asset monetisation — remaining IP families or know-how.
  • Low-cost optionality — minimal annual cost base makes small licence fees material.

Threats

  • Dilution — repeated placements at discounts (latest at EUR 0.20, 15% discount).
  • Minority-shareholder squeeze — Fortress at ≈ 68.8% of votes.
  • Patent expiry/invalidity — ageing filings and limited defence resources.
  • Contingent liabilities — Dartmouth/Celdara consideration reduces licensing economics.
  • Liquidation risk — if Fortress stops funding.
  • Counterparty risk — CellProthera's ability to fund Phase 3.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025FY2024 results: net loss EUR 5.8M; treasury EUR 4.2M; runway into Q3 2025Going-concern pressure
24 Jun 2025Strategic review announcedOpens door to asset sales/restructuring
29 Jul 2025EUR 1M Fortress private placementBridge funding
14 Aug 2025Transparency notification (Art. 14)Shareholding change following placement
25–26 Aug 2025Discontinuation of all R&D; workforce cut; runway to mid-Q4 2025End of Celyad as an R&D company
25 Sep 2025H1 2025 results: loss EUR 3.7M; cash EUR 0.8M; runway into Q4 2025Liquidity critical
30 Sep 2025Research facility divestiture (EUR 3M)Cash injection
25 Nov 2025Regulated release (subject not captured)—
12 Feb 2026C-CATHez sold to CellProthera (up to EUR 5M + royalties)Converts legacy asset into contingent value
2 Apr 2026FY2025 results: net profit EUR 0.83M (one-offs); treasury EUR 1.7M; runway into Q3 2026; BDO going-concern paragraphNot self-funding
2 Apr 2026Alarm-bell procedure triggered (net assets < 25% of capital, BE-GAAP)Shareholder vote on continuation
17 Apr 2026 (planned)Special board report under Art. 7:228 BCCAContinuation rationale
20 May 2026AGM: accounts, discharge, mandate renewals; continuationCompany continues
12 Jun 2026Share price ≈ USD 0.30Micro-cap
14 Jul 2026EUR 0.5M placement with Fortress agreedRelated-party funding
16 Jul 20262.5M shares issuedFortress ≈ 60.5% shares / ≈ 68.8% votes
22 Jul 2026Article 15 update on voting rights and shares; AGM minutes filedCapital-structure update
28 Jul 2026Transparency notification from TolefiLikely threshold change from dilution
23 Sep 2026H1 2026 results: net loss EUR 1.2M; cash EUR 0.1M; runway "until 2027"Minimal burn
8 Oct 2026Commentary highlights cash of EUR 0.1M and reduced lossesInvestor focus on survival
16 Oct 2026Share price EUR 0.174 (Frankfurt)≈ EUR 8M market cap

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue rose from EUR 0 Mn in FY2021 to EUR 0 Mn in FY2025.
Celyad Oncology SA — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2024FY2025
Revenue000.20
Gross profit——0.20

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.